Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.69 USD | +1.81% | +2.42% | -14.65% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.65% | 136M | C | ||
+19.44% | 124B | B+ | ||
+20.01% | 114B | B+ | ||
+21.11% | 25.83B | B | ||
-23.72% | 19.42B | B+ | ||
-18.17% | 16.2B | A- | ||
-19.87% | 15.31B | B | ||
+55.81% | 14.32B | C+ | ||
+8.76% | 14.31B | C+ | ||
-48.79% | 14.19B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PRQR Stock
- Ratings ProQR Therapeutics N.V.